Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers. — CFSMEATLAS
Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers.
This study examined immune cells called CD8+ T lymphocytes in ME/CFS patients and found they show higher levels of activation markers (CD38 and HLA-DR) compared to healthy people and those with regular fatigue. The researchers measured 139 ME/CFS patients, 65 with chronic fatigue, and 40 healthy controls, finding distinct immune patterns in ME/CFS that don't appear to be directly linked to inflammation, gut problems, or oxidative stress.
Why It Matters
This study identifies potential immune biomarkers specific to ME/CFS that could help differentiate it from other fatigue conditions and may guide development of subgroup-specific treatments. The finding that CD8+ activation occurs independently of classic inflammatory pathways suggests ME/CFS involves distinct immune mechanisms worth targeting therapeutically.
Observed Findings
CD8+, CD8+CD38+, and CD8+HLA-DR+ cell proportions were significantly higher in ME/CFS patients than in healthy controls
CD19+ cell percentages and CD4+/CD8+ ratios were significantly lower in both ME/CFS and CF groups compared to controls
Inverse correlations existed between CD38 expression (especially on CD8+ cells) and both the CD4+/CD8+ ratio and CD19+ expression
No significant associations were found between activation markers and biomarkers of oxidative/nitrosative stress, leaky gut, or standard cytokine/autoimmune markers
Inferred Conclusions
Increased CD38 and HLA-DR expression on CD8+ T cells represent potential biomarkers specific to ME/CFS that distinguish it from chronic fatigue alone
CD38 antigen expression may suppress CD4+/CD8+ ratio and CD19+ expression through immune-suppressive mechanisms
ME/CFS comprises distinct immune subgroups with some patients showing CD8+ activation independent of inflammation or oxidative stress pathways
Viral infection or reactivation may be involved in CD8+ activation in at least some ME/CFS patients
Remaining Questions
Do longitudinal changes in CD8+ activation markers correlate with clinical improvement or symptom worsening?
What mechanisms explain the inverse correlation between CD38 expression and CD4+/CD8+ ratio—is this direct suppression or shifts in lymphocyte populations?
What This Study Does Not Prove
This cross-sectional study cannot establish causation or whether CD8+ activation causes ME/CFS symptoms or is a consequence of the disease. The lack of association with oxidative stress and inflammation biomarkers doesn't exclude these as contributors in subsets of patients, nor does it prove viral reactivation is occurring—only that it may warrant investigation.
Can CD8+ activation status be used to predict treatment response or identify which ME/CFS patients would benefit from different therapeutic approaches?
What specific viral reactivations, if any, drive CD8+ activation in ME/CFS patients, and can they be detected through direct viral serology?